Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 8:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 371 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Hemodialysis treatment Clear all
Completed Not applicable Interventional Results available

Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft

NCT02649946
View directory record Official record
Conditions
Stenosis, Restenosis
Interventions
Covera Vascular Covered Stent following PTA, Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon
Device · Procedure
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
16
States / cities
Tempe, Arizona • Laguna Hills, California • Englewood, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Sep 29, 2026, 8:38 AM EDT
Active, not recruiting Phase 4 Interventional

Nasal Decolonization of Dialysis Patients Noses

NCT04210505
View directory record Official record
Conditions
Staphylococcus Aureus Infection
Interventions
Povidone-Iodine Topical Ointment, Standard Care
Drug · Other
Lead sponsor
Marin L. Schweizer, PhD
Other
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 29, 2026, 8:38 AM EDT
Not listed Phase 4 Interventional

A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

NCT01731301
View directory record Official record
Conditions
Chronic Hepatitis C, End Stage Renal Disease
Interventions
Ribavirin, Peginterferon, Boceprevir
Drug
Lead sponsor
Liver Institute of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Sep 29, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

NCT07348237
View directory record Official record
Conditions
Chronic Kidney Failure, End-Stage Renal Disease, Renal Impairment
Interventions
MK-2828
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
24 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 29, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

NCT01414075
View directory record Official record
Conditions
Dialysis, Anemia
Interventions
Roxadustat, Oral Iron, IV Iron
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Northridge, California • Yuba City, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Sep 29, 2026, 8:38 AM EDT
Recruiting Not applicable Interventional

Community Health Workers in an Interdisciplinary Outpatient CKD Clinic to Optimize Social Care Navigation, Patient Engagement, and Home Dialysis Utilization

NCT06925776
View directory record Official record
Conditions
Kidney Replacement Therapy
Interventions
CHOOSE Home Intervention, Usual Care
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 29, 2026, 8:38 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment

NCT02508740
View directory record Official record
Conditions
Renal Impairment
Interventions
bevenopran
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced Sep 29, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV

NCT00949234
View directory record Official record
Conditions
HIV Prevention, HIV Infections
Interventions
tenofovir + emtricitabine, lopinavir/ritonavir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Sep 29, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

NCT01977482
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo, rhEPO
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Azusa, California • Los Angeles, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 29, 2026, 8:38 AM EDT
Completed Not applicable Interventional

Acute Effects of Intradialytic Exercise on Cardiovascular Function in Hemodialysis Patients

NCT02753868
View directory record Official record
Conditions
Kidney Failure
Interventions
exercise, Hemodialysis treatment
Behavioral · Procedure
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 29, 2026, 8:38 AM EDT
Completed Not applicable Interventional Results available

Impact of Vitamin D Repletion in Hemodialysis Patients

NCT01175798
View directory record Official record
Conditions
Vitamin D Deficiency, End-stage Renal Disease
Interventions
Cholecalciferol
Drug
Lead sponsor
Mehrotra, Anita, M.D.
Individual
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 29, 2026, 8:38 AM EDT
Withdrawn Phase 4 Interventional

A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.

NCT00312767
View directory record Official record
Conditions
Fabry Disease
Interventions
Fabrazyme (agalsidase beta)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Sep 29, 2026, 8:38 AM EDT
Completed Phase 2 Interventional

The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients

NCT00179218
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
nutritional supplementation, exercise
Drug · Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2009 · Synced Sep 29, 2026, 8:38 AM EDT
Completed Not applicable Interventional

Investigating the Effectiveness of Intradialytic Massage on Cramping in Dialysis Patients

NCT01944280
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
massage
Other
Lead sponsor
Catherine Sullivan
Other
Eligibility
18 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 29, 2026, 8:38 AM EDT
Completed Phase 4 Interventional Results available

Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients

NCT03781089
View directory record Official record
Conditions
Hyperkalemia, End Stage Renal Disease
Interventions
Patiromer Oral Powder Product
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 29, 2026, 8:38 AM EDT
Active, not recruiting Phase 1 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions
Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 29, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Results available

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

NCT02833857
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Louisville, Kentucky • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 29, 2026, 8:38 AM EDT
Recruiting Not applicable Interventional

Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility

NCT05407207
View directory record Official record
Conditions
Diabetes Mellitus, Hemodialysis Complication, Cardiovascular Complication, Quality of Life
Interventions
Tennant Biomodulator ®
Device
Lead sponsor
Hamad Medical Corporation
Industry
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 29, 2026, 8:38 AM EDT
Completed No phase listed Observational

Mechanisms and Treatment of Intradialytic Hypertension - Sodium

NCT01371890
View directory record Official record
Conditions
Hemodialysis, End-stage Renal Disease, Hypertension, Intradialytic Hypertension
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 29, 2026, 8:38 AM EDT
Completed Phase 4 Interventional Results available

Iron Indices and Intravenous Ferumoxytol: Time to Steady State

NCT01148745
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
ferumoxytol
Drug
Lead sponsor
Dialysis Clinic, Inc.
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 29, 2026, 8:38 AM EDT
Terminated Not applicable Interventional Results available

HiLo: Pragmatic Trial of Higher vs Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis

NCT04095039
View directory record Official record
Conditions
All-cause Mortality, Hospitalization
Interventions
Hemodialysis
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
84
States / cities
Birmingham, Alabama • Phoenix, Arizona • Camden, Arkansas + 75 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 29, 2026, 8:38 AM EDT
Completed Not applicable Interventional

The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300

NCT05947708
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis
Interventions
Dialysate Flow Rate
Device
Lead sponsor
Outset Medical
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 29, 2026, 8:38 AM EDT
Terminated Phase 2 Interventional

A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD

NCT01873534
View directory record Official record
Conditions
Anemia of Chronic Disease
Interventions
FMX-8
Drug
Lead sponsor
FerruMax Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Arvada, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Sep 29, 2026, 8:38 AM EDT
Terminated Phase 3 Interventional Results available

Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections

NCT01483872
View directory record Official record
Conditions
Infection; Dialysis Catheter
Interventions
NAC/Tigecycline/Heparin combination lock solution, Standard anticoagulant (Heparin or Citrate)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 29, 2026, 8:38 AM EDT